论文部分内容阅读
最近山德士(Sandoz)药厂在雅典召开国际性会议,介绍尚在试制的新型钙拮抗剂Isradipine,即双氢吡啶钙拮抗剂。其作用主要是抑制慢通道,具有显著的组织选择性。(1)对心脏无药理作用,不影响心率和心排血量,对Q-T间期亦无影响。对任何年龄组特别老年病例亦无禁忌证。(2)它是一种单纯强有力的血管扩张剂,对冠状动脉、脑动脉、肾动脉及骨胳肌动脉扩张效率约80％,且对老年或低血浆肾素病例疗效较好,对凡能受钙离子调节血管床使肌肉收缩的药物如L型钙通道药物、血管紧张素Ⅱ或去甲肾上腺素等均受到抑制。用法:降压剂量从1.25mg/d开始,渐增为2.5～5.0mg/d,总量应≤10～15mg/d。服后2～4h血压开始下降,持续约12h。认为每4周调整剂量为宜。
Recently, Sandoz Pharmaceutical Factory held an international conference in Athens to introduce the new calcium antagonist Isradipine, which is still under trial, and is a calcium dihydropyridine antagonist. Its main role is to inhibit the slow channel, with significant tissue selectivity. (1) no pharmacological effects on the heart, does not affect the heart rate and cardiac output, Q-T interval has no effect. There is no contraindication for special elderly cases of any age group. (2) It is a simple and powerful vasodilator with an approximate 80% efficiency in the expansion of coronary arteries, cerebral arteries, renal arteries and skeletal muscular arteries and is superior to older or lower plasma renin cases. Drugs that modulate muscle contraction by calcium ions, such as L-type calcium channel drugs, angiotensin II or norepinephrine, are all inhibited. Usage: blood pressure dose starting from 1.25mg / d, increasing to 2.5 ~ 5.0mg / d, the total should be ≤ 10 ~ 15mg / d. 2 ~ 4h after taking blood pressure began to decline, lasted about 12h. It is advisable to adjust the dosage every 4 weeks.